What strategies do you use to optimize tolerability of anti-MAC regimens? Do you ever deploy agents sequentially, or at lower doses, or reduced frequency, and if so, why? And for how long? How successful is this approach?

What strategies do you use to optimize tolerability of anti-MAC regimens? Do you ever deploy agents sequentially, or at lower doses, or reduced frequency, and if so, why? And for how long? How successful is this approach?

CLICK HERE FOR CME CREDIT

What strategies do you use to optimize tolerability of anti-MAC regimens? Do you ever deploy agents sequentially, or at lower doses, or reduced frequency, and if so, why? And for how long? How successful is this approach?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina